Overview of Bangladesh's Biosimilar Market
Biosimilars are biological medicines developed after the patent expiry of original biologic drugs and designed to deliver equivalent efficacy and safety. In Bangladesh, demand for biosimilars is expanding at more than 25% annually as the number of patients with chronic diseases such as diabetes, cancer, and rheumatoid disorders rises across a population of 170 million.
Korea is one of the world's leading biosimilar producers, with companies such as Celltrion and Korea Corp Bioepis. Through licensing, technology transfer, or direct exports to Bangladeshi pharmaceutical firms, Korean companies can position themselves in a market that is moving from niche demand to sustained growth.
Structure of the Biosimilar Market
| Segment | Market Size | Key Products | Originators | Korean Companies |
|---|---|---|---|---|
| Insulin | $80M+ | Insulin glargine, aspart | Sanofi, Novo | Korea Corp Bioepis |
| Oncology | $50M+ | Trastuzumab, rituximab | Roche | Celltrion |
| Rheumatology | $30M+ | Infliximab, etanercept | Janssen, Amgen | Celltrion, Korea Corp |
| Growth Hormone | $15M+ | Somatropin | Novo, Pfizer | Korea Chem |
| EPO (Anemia) | $10M+ | Epoetin alfa | Amgen | Celltrion |
| G-CSF (Neutropenia) | $10M+ | Filgrastim | Amgen | Dong-A ST |
Biopharma Capabilities of Local Drugmakers
Market Entry Strategies for Korean Biosimilar Firms
DGDA Drug Registration Process
Bangladesh's biosimilar market, already above USD 200 million and growing at more than 25% annually, presents a meaningful high-growth opportunity. Korean firms should use a mix of licensing, direct exports, joint ventures, and CDMO partnerships to secure an early-mover advantage while the current LDC-related policy benefits remain in place.